Latest News and Press Releases

EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040 Galderma...

TWYNEO is the first-ever tretinoin and benzoyl peroxide combination to treat facial acneSol-Gel’s U.S. commercialization partner, Galderma, launched TWYNEO® in the U.S. at the Annual Meeting of the...

Galderma launched TWYNEO® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially available in Spring 2022.2021 revenue of $31.3...

NESS ZIONA, Israel, March 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and...

NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded...

FDA informs Sol-Gel that it intends to conduct a pre-approval inspection of the production site for EPSOLAY during the week of February 14th, 2022 NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE...

Sol-Gel attains a profitable quarter, reporting total revenues of $8.8 million, net income of $1.3 million and EPS of $0.06Recently obtained FDA approval of TWYNEO® triggers a $3.5 million milestone...

NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic...

-  Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs -  Sol-Gel to retain two generic...

NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic...